InTandem Senior Managing Director, Brad Coppens, and Vivo Infusion CEO, Chris Reef, spoke with Sarah Pringle from Axios about the firm’s creation and launch of Vivo Infusion and the current landscape of increasing demand for infusion and injection care contrasted with payors who are hesitant to pay “ballooning pharmaceutical and infusible pharmaceutical costs.” In addition to today’s revenue generation of already $200 million, Mr. Coppens also discussed the exciting growth potential of the company.
“In as little as three years, over 50% of infusion treatment will occur in ambulatory infusion centers.”
Read the full article by clicking here.
